{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:59:19Z","timestamp":1777111159702,"version":"3.51.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Oral Invest"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00784-019-02886-0","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T10:04:12Z","timestamp":1554804252000},"page":"4371-4382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review"],"prefix":"10.1007","volume":"23","author":[{"given":"Sic\u00edlia Rezende","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana Gravito","family":"de Azevedo Branco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda Leal","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise Vieira","family":"Travassos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo Henrique Romani","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe Paiva","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Alves","family":"Mesquita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2258-8071","authenticated-orcid":false,"given":"Lucas Guimar\u00e3es","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarc\u00edlia Aparecida","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"key":"2886_CR1","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1002\/cncr.11316","volume":"97","author":"Y Xie","year":"2003","unstructured":"Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA (2003) Trends in leukemia incidence and survival in the United States (1973\u20131998). Cancer 97:2229\u20132235","journal-title":"Cancer"},{"key":"2886_CR2","doi-asserted-by":"crossref","unstructured":"Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) American Cancer Society, Cancer statistics. CA Cancer J Clin 54:8\u201329","DOI":"10.3322\/canjclin.54.1.8"},{"key":"2886_CR3","first-page":"85","volume":"25","author":"PC Nowell","year":"1960","unstructured":"Nowell PC, Hungerford DA (1960) Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 25:85\u2013109","journal-title":"J Natl Cancer Inst"},{"key":"2886_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290\u2013293","journal-title":"Nature"},{"key":"2886_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/315550a0","volume":"315","author":"E Shtivelman","year":"1985","unstructured":"Shtivelman E, Lifshitz B, Gale RP, Canaani E (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315:550\u2013554","journal-title":"Nature"},{"key":"2886_CR6","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1084\/jem.145.6.1567","volume":"145","author":"S Abramson","year":"1977","unstructured":"Abramson S, Miller RG, Phillips RA (1977) The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. J Exp Med 145:1567\u20131579","journal-title":"J Exp Med"},{"key":"2886_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271\u2013289","journal-title":"CA Cancer J Clin"},{"key":"2886_CR8","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1182\/blood.V91.11.3995","volume":"91","author":"S Faderl","year":"1998","unstructured":"Faderl S, Kantarjian HM, Talpaz M, Estrov Z (1998) Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91:3995\u20134019","journal-title":"Blood"},{"key":"2886_CR9","first-page":"957","volume":"10","author":"S Schlieben","year":"1996","unstructured":"Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, Schrappe M, Repp R, Zimmermann M, Kabisch H, Janka-Schaub G, Bartram CR, Ludwig WD, Riehm H, Lampert F, Harbott J (1996) Incidence and clinical outcome of children with BCR\/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 10:957\u2013963","journal-title":"Leukemia"},{"key":"2886_CR10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/sj.leu.2403006","volume":"17","author":"R Hehlmann","year":"2003","unstructured":"Hehlmann R, Berger U, Pfirrmann M et al (2003) Randomized comparison of interferon \u03b1 and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon \u03b1 and hydroxyurea. Leukemia 17:1529\u20131537","journal-title":"Leukemia"},{"key":"2886_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/TCRM.S1527","volume":"4","author":"M Henkes","year":"2008","unstructured":"Henkes M, van der Kuip H, Aulitzky WE (2008) Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec\u00ae, Gleevec\u2122). Ther Clin Risk Manag 4:163","journal-title":"Ther Clin Risk Manag"},{"key":"2886_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1046\/j.0307-6938.2001.00947.x","volume":"27","author":"B Kumar","year":"2002","unstructured":"Kumar B, Saraswat A, Kaur I (2002) Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients. Clin Exp Dermatol 27:8\u201313","journal-title":"Clin Exp Dermatol"},{"key":"2886_CR13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra013339","volume":"346","author":"DG Savage","year":"2002","unstructured":"Savage DG, Antman KH (2002) Imatinib mesylate\u2014a new oral targeted therapy. New Engl J Med 346:683\u2013693","journal-title":"New Engl J Med"},{"key":"2886_CR14","doi-asserted-by":"publisher","first-page":"7555","DOI":"10.7314\/APJCP.2015.16.17.7555","volume":"16","author":"M Payandeh","year":"2015","unstructured":"Payandeh M, Sadeghi M, Sadeghi E (2015) Treatment and survival in patients with chronic myeloid leukemia in a chronic phase in West Iran. Asian Pac J Cancer Prev 16:7555\u20137559","journal-title":"Asian Pac J Cancer Prev"},{"key":"2886_CR15","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, Faderl S, Cortes J (2004) Treatment of Philadelphia chromosome\u2013positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103:4396\u20134407","journal-title":"Blood"},{"key":"2886_CR16","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/cncr.22881","volume":"110","author":"PP Piccaluga","year":"2007","unstructured":"Piccaluga PP, Paolini S, Martinelli G (2007) Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer 110:1178\u20131186","journal-title":"Cancer"},{"key":"2886_CR17","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U K, Staten AM, Pazdur R (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935\u2013942","journal-title":"Clin Cancer Res"},{"key":"2886_CR18","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","volume":"21","author":"MW Deininger","year":"2003","unstructured":"Deininger MW, O\u2019brien SG, Ford JM, Druker BJ (2003) Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21:1637\u20131647","journal-title":"J Clin Oncol"},{"key":"2886_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000063899","volume":"205","author":"DS Lim","year":"2002","unstructured":"Lim DS, Muir J (2002) Oral lichenoid reaction to imatinib (STI 571, Gleevec). Dermatology 205:169\u2013171","journal-title":"Dermatology"},{"key":"2886_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/09546630410015556","volume":"15","author":"P Ena","year":"2004","unstructured":"Ena P, Chiarolini F, Siddi GM, Cossu A (2004) Oral lichenoid eruption secondary to imatinib (Glivec\u00ae). J Dermatol Treat 15:253\u2013255","journal-title":"J Dermatol Treat"},{"key":"2886_CR21","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/j.1365-4632.2006.03171.x","volume":"45","author":"JC Pascual","year":"2006","unstructured":"Pascual JC, Matarredona J, Miralles J, Conesa V, Borras-Blasco J (2006) Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases. Int J Dermatol 45:1471\u20131473","journal-title":"Int J Dermatol"},{"key":"2886_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.tripleo.2010.11.006","volume":"111","author":"U Mattsson","year":"2011","unstructured":"Mattsson U, Halbritter S, Serikoff EM, Christerson L, Warfvinge G (2011) Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111:12\u201316","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"2886_CR23","doi-asserted-by":"crossref","unstructured":"Wong M, Sade S, Gilbert M, Klieb HB (2011) Oral melanosis after tyrosine kinase inhibition with imatinib for chronic myelogenous leukemia: report of a case and review of the literature. Dermatol Online J 17:4","DOI":"10.5070\/D3498194BX"},{"key":"2886_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s12105-011-0325-4","volume":"6","author":"CC Li","year":"2012","unstructured":"Li CC, Malik SM, Blaeser BF, Dehni WJ, Kabani SP, Boyle N, Toner M, Woo SB (2012) Mucosal pigmentation caused by imatinib: report of three cases. Head Neck Pathol 6:290\u2013295","journal-title":"Head Neck Pathol"},{"key":"2886_CR25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3109\/10428194.2012.702904","volume":"54","author":"TL Khoo","year":"2013","unstructured":"Khoo TL, Catalano A, Supple S, Chong L, Yeoh SC, Yeung S, Iland H (2013) Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT. Leuk Lymphoma 54:186\u2013188","journal-title":"Leuk Lymphoma"},{"key":"2886_CR26","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/ajh.23589","volume":"89","author":"LE Roeker","year":"2014","unstructured":"Roeker LE, Wolanskyj AP (2014) Imatinib-associated melanosis of the palate. Am J Hematol 89:564\u2013564","journal-title":"Am J Hematol"},{"key":"2886_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.oooo.2017.10.006","volume":"125","author":"KI Tosios","year":"2018","unstructured":"Tosios KI, Kalogirou EM, Sklavounou A (2018) Drug-associated hyperpigmentation of the oral mucosa: report of 4 cases. Oral Surg Oral Med Oral Pathol Oral Radiol 125:54\u201366","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"2886_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/MPH.0b013e318033a76c","volume":"29","author":"N Singh","year":"2007","unstructured":"Singh N, Bakhshi S (2007) Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia. J Pediatr Hematol Oncol 29:208\u2013209","journal-title":"J Pediatr Hematol Oncol"},{"key":"2886_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1468-3083.2008.02706.x","volume":"23","author":"T Mcpherson","year":"2009","unstructured":"Mcpherson T, Sherman V, Turner R (2009) Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol 23:82\u201383","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2886_CR30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jcms.2011.07.010","volume":"40","author":"RG Resende","year":"2012","unstructured":"Resende RG, Teixeira RGL, de Oliveira Vasconcelos F, de Souza Silva ME, Abreu MHG, Gomez RS (2012) Imatinib-associated hyperpigmentation of the palate in post-HSCT patient. J Cranio-Maxillofac Surg 40:140\u2013143","journal-title":"J Cranio-Maxillofac Surg"},{"key":"2886_CR31","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1365-2230.2011.04196.x","volume":"37","author":"JC Steele","year":"2012","unstructured":"Steele JC, Triantafyllou A, Rajlawat BP, Field EA (2012) Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib. Clin Exp Dermatol 37:432\u2013433","journal-title":"Clin Exp Dermatol"},{"key":"2886_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4321\/S0213-12852013000600005","volume":"29","author":"J L\u00f3pez-Labady","year":"2013","unstructured":"L\u00f3pez-Labady J, Villarroel-Dorrego M, Bascones Mart\u00ednez A (2013) Pigmentaci\u00f3n inusual del paladar asociada a imatinib: reporte de caso cl\u00ednico. Av Odontoestomatol 29:309\u2013314","journal-title":"Av Odontoestomatol"},{"key":"2886_CR33","doi-asserted-by":"publisher","first-page":"532","DOI":"10.5021\/ad.2014.26.4.532","volume":"26","author":"HS Song","year":"2014","unstructured":"Song HS, Kang HY (2014) Imatinib mesylate-induced hyperpigmentation of the nose and palate. Ann Dermatol 26:532\u2013533","journal-title":"Ann Dermatol"},{"key":"2886_CR34","doi-asserted-by":"crossref","unstructured":"Lyne A, Creedon A, Bailey BM (2015) Mucosal pigmentation of the hard palate in a patient taking imatinib. BMJ Case Rep pii: bcr2015209335","DOI":"10.1136\/bcr-2015-209335"},{"key":"2886_CR35","doi-asserted-by":"crossref","unstructured":"Romeo U, Palaia G, Fantozzi PJ, Tenore G, Bosco D (2015) A rare case of melanosis of the hard palate mucosa in a patient with chronic myeloid leukemia. Case Rep Dent 817094","DOI":"10.1155\/2015\/817094"},{"key":"2886_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40902-017-0136-y","volume":"39","author":"GP Bombeccari","year":"2017","unstructured":"Bombeccari GP, Garagiola U, Pallotti F, Rossi M, Porrini M, Giann\u00ec AB, Spadari F (2017) Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib. Maxillofac Plast Reconstr Surg 39:37","journal-title":"Maxillofac Plast Reconstr Surg"},{"key":"2886_CR37","doi-asserted-by":"crossref","unstructured":"Di Tullio F, Mandel VD, Scotti R, Padalino C, Pellacani G (2018) Imatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature. Int J Dermatol 57: 784\u2013790","DOI":"10.1111\/ijd.13931"},{"key":"2886_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.tripleo.2011.03.046","volume":"112","author":"CC Torres-Pereira","year":"2011","unstructured":"Torres-Pereira CC (2011) Are we ready to blame imatinib for palatal pigmentation? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:287","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"2886_CR39","volume-title":"Cancer treatment and survivorship facts & figures 2016\u20132017","author":"American Cancer Society","year":"2016","unstructured":"American Cancer Society (2016) Cancer treatment and survivorship facts & figures 2016\u20132017. American Cancer Society, Atlanta"},{"key":"2886_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1586\/14737140.4.1.85","volume":"4","author":"A Redaelli","year":"2004","unstructured":"Redaelli A, Bell C, Casagrande J, Stephens J, Botteman M, Laskin B, Pashos C (2004) Clinical and epidemiologic burden of chronic myelogenous leukemia. Expert Rev Anticancer Ther 4:85\u201396","journal-title":"Expert Rev Anticancer Ther"},{"key":"2886_CR41","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, D\u00fcrnberger G et al (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110:4055\u20134063","journal-title":"Blood"},{"key":"2886_CR42","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","volume":"344","author":"JM Goldman","year":"2001","unstructured":"Goldman JM, Melo JV (2001) Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med 344:1084\u20131086","journal-title":"New Engl J Med"},{"key":"2886_CR43","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D'Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Piazza R, Valsecchi MG, Kim DW (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103:553\u2013561","journal-title":"J Natl Cancer Inst"},{"key":"2886_CR44","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4103\/2279-042X.128145","volume":"2","author":"P Jain","year":"2013","unstructured":"Jain P, Das VNR, Ranjan A, Chaudhary R, Pandey K (2013) Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or hydroxyurea. J Res Pharm Pract 2:156\u2013161","journal-title":"J Res Pharm Pract"},{"key":"2886_CR45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.leukres.2017.08.014","volume":"61","author":"K Airiau","year":"2017","unstructured":"Airiau K, Turcq B, Mahon FX, Belloc F (2017) A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line. Leuk Res 61:44\u201352","journal-title":"Leuk Res"},{"key":"2886_CR46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.pai.0000173054.83414.22","volume":"13","author":"M Miettinen","year":"2005","unstructured":"Miettinen M, Lasota J (2005) KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 13:205\u2013220","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2886_CR47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1755-148X.2008.00519.x","volume":"22","author":"S Jeon","year":"2009","unstructured":"Jeon S, Kim NH, Kim JY, Lee AY (2009) Stem cell factor induces ERM proteins phosphorylation through PI3K activation to mediate melanocyte proliferation and migration. Pigment Cell Melanoma Res 22:77\u201385","journal-title":"Pigment Cell Melanoma Res"},{"key":"2886_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1034\/j.1600-0749.2003.00055.x","volume":"16","author":"B Wehrle-Haller","year":"2003","unstructured":"Wehrle-Haller B (2003) The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Melanoma Res 16:287\u2013296","journal-title":"Pigment Cell Melanoma Res"},{"key":"2886_CR49","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1365-2133.2006.07359.x","volume":"155","author":"M Cario-Andr\u00e9","year":"2006","unstructured":"Cario-Andr\u00e9 M, Ardilouze L, Pain C, Gauthier Y, Mahon FX, Taieb A (2006) Imatinib mesilate inhibits melanogenesis in vitro. Br J Dermatol 155:493\u2013494","journal-title":"Br J Dermatol"},{"key":"2886_CR50","first-page":"139","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139\u2013145","journal-title":"J Pharmacol Exp Ther"},{"key":"2886_CR51","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/annonc\/mdh068","volume":"15","author":"B Arora","year":"2004","unstructured":"Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V (2004) Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 15:358\u2013359","journal-title":"Ann Oncol"},{"key":"2886_CR52","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/1078-0432.CCR-03-0110","volume":"10","author":"ME Robson","year":"2004","unstructured":"Robson ME, Glogowski E, Sommer G, Antonescu CR, Nafa K, Maki RG, Ellis N, Besmer P, Brennan M, Offit K (2004) Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res 10:1250\u20131254","journal-title":"Clin Cancer Res"},{"key":"2886_CR53","doi-asserted-by":"crossref","unstructured":"Alexandrescu DT, Dasanu CA, Farzanmehr H, Kauffman CL (2008) Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J 14:7","DOI":"10.5070\/D3472203P2"},{"key":"2886_CR54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tripleo.2008.07.022","volume":"107","author":"MA Lerman","year":"2009","unstructured":"Lerman MA, Karimbux N, Guze KA, Woo SB (2009) Pigmentation of the hard palate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107:8\u201312","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"2886_CR55","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/cup.12182","volume":"40","author":"BAB Andrade de","year":"2013","unstructured":"de Andrade BAB, Fonseca FP, Pires FR, Mesquita ATM, Falci SGM, dos Santos Silva AR, Vargas PA, Jorge J, de Almeida OP (2013) Hard palate hyperpigmentation secondary to chronic chloroquine therapy: report of five cases. J Cutan Pathol 40:833\u2013838","journal-title":"J Cutan Pathol"},{"key":"2886_CR56","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.tripleo.2007.07.047","volume":"105","author":"M Meleti","year":"2008","unstructured":"Meleti M, Vescovi P, Mooi WJ, van der Waal I (2008) Pigmented lesions of the oral mucosa and perioral tissues: a flow-chart for the diagnosis and some recommendations for the management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105:606\u2013616","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"2886_CR57","doi-asserted-by":"publisher","first-page":"919","DOI":"10.4317\/medoral.17679","volume":"17","author":"RO Gondak","year":"2012","unstructured":"Gondak RO, da Silva-Jorge R, Jorge J, Lopes MA, Vargas PA (2012) Oral pigmented lesions: clinicopathologic features and review of the literature. Med Oral Patol Oral Cir Bucal 17:919","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"2886_CR58","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0738-081X(00)00148-6","volume":"18","author":"D Eisen","year":"2000","unstructured":"Eisen D (2000) Disorders of pigmentation in the oral cavity. Clin Dermatol 18:579\u2013587","journal-title":"Clin Dermatol"},{"key":"2886_CR59","first-page":"682","volume":"70","author":"ABDS Kauzman","year":"2004","unstructured":"Kauzman ABDS, Pavone M, Blanas N, Bradley G (2004) Pigmented lesions of the oral cavity: review, differential diagnosis, and case presentations. J Can Dent Assoc 70:682\u2013683","journal-title":"J Can Dent Assoc"},{"key":"2886_CR60","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1600-0722.1982.tb00760.x","volume":"90","author":"T Axeix","year":"1982","unstructured":"Axeix T, HEDIN CA (1982) Epidemiologic study of excessive oral melanin pigmentation with special reference to the influence of tobacco habits. Eur J Oral Sci 90:434\u2013442","journal-title":"Eur J Oral Sci"},{"key":"2886_CR61","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1046\/j.1468-3083.2000.00143.x","volume":"14","author":"P Lenane","year":"2000","unstructured":"Lenane P, Powell FC (2000) Oral pigmentation. J Eur Acad Dermatol Venereol 14:448\u2013465","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2886_CR62","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1067\/moe.2000.106340","volume":"90","author":"CL Kleinegger","year":"2000","unstructured":"Kleinegger CL, Hammond HL, Finkelstein MW (2000) Oral mucosal hyperpigmentation secondary to antimalarial drug therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90:189\u2013194","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"2886_CR63","first-page":"87","volume":"11","author":"HW Kim","year":"1988","unstructured":"Kim HW (1988) Generalized oral and cutaneous hyperpigmentation in Addison's disease. Odontostomatol Trop= Trop Dent J 11:87\u201390","journal-title":"Odontostomatol Trop= Trop Dent J"},{"key":"2886_CR64","doi-asserted-by":"crossref","first-page":"251","DOI":"10.20452\/pamw.1734","volume":"123","author":"M Machaczka","year":"2013","unstructured":"Machaczka M, Gossart M (2013) Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia. Pol Arch Med Wewn 123:251\u2013252","journal-title":"Pol Arch Med Wewn"},{"key":"2886_CR65","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1684\/ejd.2015.2684","volume":"26","author":"E Dervis","year":"2016","unstructured":"Dervis E, Ayer M, Belli AA, Barut SG (2016) Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: a six-year follow up. Eur J Dermatol 26:133\u2013137","journal-title":"Eur J Dermatol"}],"container-title":["Clinical Oral Investigations"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-019-02886-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00784-019-02886-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-019-02886-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T19:18:28Z","timestamp":1721157508000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00784-019-02886-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,9]]},"references-count":65,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2886"],"URL":"https:\/\/doi.org\/10.1007\/s00784-019-02886-0","relation":{},"ISSN":["1432-6981","1436-3771"],"issn-type":[{"value":"1432-6981","type":"print"},{"value":"1436-3771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,9]]},"assertion":[{"value":"21 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}